Fate Therapeutics sets IPO range

Stem cell company Fate Therapeutics Inc. (San Diego, Calif.) amended its IPO and now plans to sell 4 million shares at $14-$16. At the $15 midpoint, the company would raise $60 million and be valued at $218.7 million. Fate filed to raise up to $69 million in an IPO last month. Cowen; BMO Capital Markets; and Wedbush PacGrow are underwriters. ...